{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T20:43:06Z","timestamp":1791319386497,"version":"4.3.1"},"reference-count":135,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["aacejournalendocrinepractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrine Practice"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.4158\/cs-2020-0490","type":"journal-article","created":{"date-parts":[[2020,11,2]],"date-time":"2020-11-02T18:44:21Z","timestamp":1604342661000},"page":"1196-1224","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":216,"title":["Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Management of Dyslipidemia and Prevention of Cardiovascular Disease Algorithm \u2013 2020 Executive Summary"],"prefix":"10.1016","volume":"26","author":[{"given":"Yehuda","family":"Handelsman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul S.","family":"Jellinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris K.","family":"Guerin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zachary T.","family":"Bloomgarden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eliot A.","family":"Brinton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew J.","family":"Budoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael H.","family":"Davidson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Einhorn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio","family":"Fazio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivian A.","family":"Fonseca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan J.","family":"Garber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Grunberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald M.","family":"Krauss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey I.","family":"Mechanick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul D.","family":"Rosenblit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald A.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen L.","family":"Wyne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.4158\/CS-2020-0490_bb0010","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4158\/EP171764.APPGL","article-title":"American Association of Clinical Endocrinologists and American College of Endocrinology guidelines for management of dyslipidemia and prevention of atherosclerosis","volume":"23","author":"Jellinger","year":"2017","journal-title":"Endocr Pract."},{"key":"10.4158\/CS-2020-0490_bb0015","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1136\/heartjnl-2016-309573","article-title":"Trends in the epidemiology of cardiovascular disease in the UK","volume":"102","author":"Bhatnagar","year":"2016","journal-title":"Heart."},{"key":"10.4158\/CS-2020-0490_bb0020","doi-asserted-by":"crossref","first-page":"e139","DOI":"10.1161\/CIR.0000000000000757","article-title":"Heart disease and stroke statistics\u20132020 update: a report from the American Heart Association","volume":"141","author":"Virani","year":"2020","journal-title":"Circulation."},{"key":"10.4158\/CS-2020-0490_bb0025","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1111\/dom.13921","article-title":"Risk of cardiovascular events in patients with hypertriglyceridaemia: A review of real-world evidence","volume":"22","author":"Toth","year":"2020","journal-title":"Diabetes Obes Metab."},{"key":"10.4158\/CS-2020-0490_bb0030","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1093\/eurheartj\/ehx144","article-title":"Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel","volume":"38","author":"Ference","year":"2017","journal-title":"Eur Heart J."},{"key":"10.4158\/CS-2020-0490_bb0035","first-page":"1","article-title":"Prescription drug use among adults aged 40\u201379 in the United States and Canada","author":"Hales","year":"2019","journal-title":"NCHS Data Brief."},{"key":"10.4158\/CS-2020-0490_bb0040","first-page":"1","article-title":"Prevalence of obesity and severe obesity among adults: United States, 2017\u20132018","volume":"360","author":"Hales","year":"2020","journal-title":"NCHS Data Brief."},{"key":"10.4158\/CS-2020-0490_bb0055","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1161\/CIRCULATIONAHA.114.012477","article-title":"Hyperlipidemia in early adulthood increases long-term risk of coronary heart disease","volume":"131","author":"Navar-Boggan","year":"2015","journal-title":"Circulation."},{"key":"10.4158\/CS-2020-0490_bb0060","doi-asserted-by":"crossref","first-page":"3143","DOI":"10.1161\/circ.106.25.3143","article-title":"Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report","volume":"106","year":"2002","journal-title":"Circulation."},{"key":"10.4158\/CS-2020-0490_bb0065","doi-asserted-by":"crossref","first-page":"811","DOI":"10.2337\/dc08-9018","article-title":"Lipoprotein management in patients with cardiometabolic risk: consensus statement from the American Diabetes Association and the American College of Cardiology Foundation","volume":"31","author":"Brunzell","year":"2008","journal-title":"Diabetes Care."},{"key":"10.4158\/CS-2020-0490_bb0070","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1503\/cmaj.060963","article-title":"Hypertriglyceridemia: its etiology, effects and treatment","volume":"176","author":"Yuan","year":"2007","journal-title":"CMAJ."},{"key":"10.4158\/CS-2020-0490_bb0075","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.jacl.2019.04.010","article-title":"Use of Lipoprotein(a) in clinical practice: A biomarker whose time has come. A scientific statement from the National Lipid Association","volume":"13","author":"Wilson","year":"2019","journal-title":"J Clin Lipidol."},{"key":"10.4158\/CS-2020-0490_bb0080","first-page":"877","article-title":"Practical guidelines for familial combined hyperlipidemia diagnosis: an up-date","volume":"3","author":"Gaddi","year":"2007","journal-title":"Vasc Health Risk Manag."},{"key":"10.4158\/CS-2020-0490_bb0085","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.atherosclerosis.2012.02.019","article-title":"Homozygous familial hypercholesterolemia: current perspectives on diagnosis and treatment","volume":"223","author":"Raal","year":"2012","journal-title":"Atherosclerosis."},{"key":"10.4158\/CS-2020-0490_bb0090","series-title":"Dyslipidemia","author":"Davidson","year":"2019"},{"key":"10.4158\/CS-2020-0490_bb0095","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/j.amjcard.2012.04.062","article-title":"Secondary causes of dyslipidemia","volume":"110","author":"Vodnala","year":"2012","journal-title":"Am J Cardiol."},{"key":"10.4158\/CS-2020-0490_bb0100","doi-asserted-by":"crossref","first-page":"e002262","DOI":"10.1161\/CIRCIMAGING.114.002262","article-title":"Comparison of coronary artery calcium presence, carotid plaque presence, and carotid intima-media thickness for cardiovascular disease prediction in the Multi-Ethnic Study of Atherosclerosis","volume":"8","author":"Gepner","year":"2015","journal-title":"Circ Cardiovasc Imaging."},{"key":"10.4158\/CS-2020-0490_bb0105","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.amjcard.2004.03.023","article-title":"Framingham risk score and prediction of lifetime risk for coronary heart disease","volume":"94","author":"Lloyd-Jones","year":"2004","journal-title":"Am J Cardiol."},{"key":"10.4158\/CS-2020-0490_bb0110","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1001\/jama.297.6.611","article-title":"Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds Risk Score","volume":"297","author":"Ridker","year":"2007","journal-title":"JAMA."},{"key":"10.4158\/CS-2020-0490_bb0115","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1042\/cs1010671","article-title":"The UKPDS risk engine: a model for the risk of coronary heart disease in type II diabetes (UKPDS 56)","volume":"101","author":"Stevens","year":"2001","journal-title":"Clin Sci."},{"key":"10.4158\/CS-2020-0490_bb0120","first-page":"S49","article-title":"2013 ACC\/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines","volume":"129","author":"Goff","year":"2013","journal-title":"Circulation."},{"key":"10.4158\/CS-2020-0490_bb0125","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","article-title":"Alirocumab and cardiovascular outcomes after acute coronary syndrome","volume":"379","author":"Schwartz","year":"2018","journal-title":"N Engl J Med."},{"key":"10.4158\/CS-2020-0490_bb0130","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N Engl J Med."},{"key":"10.4158\/CS-2020-0490_bb0135","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","article-title":"Ezetimibe added to statin therapy after acute coronary syndromes","volume":"372","author":"Cannon","year":"2015","journal-title":"N Engl J Med."},{"key":"10.4158\/CS-2020-0490_bb0140","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0140-6736(02)09327-3","article-title":"MRC\/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial","volume":"360","year":"2002","journal-title":"Lancet."},{"key":"10.4158\/CS-2020-0490_bb0145","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1016\/S0140-6736(02)11600-X","article-title":"Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial","volume":"360","author":"Shepherd","year":"2002","journal-title":"Lancet."},{"key":"10.4158\/CS-2020-0490_bb0150","first-page":"1149","volume":"361","author":"Sever","year":"2003","journal-title":"J Am Coll Cardiol."},{"key":"10.4158\/CS-2020-0490_bb0155","first-page":"1644","article-title":"Relative efficacy of atorvastatin 80 mg and pravastatin 40 mg in achieving the dual goals of low-density lipoprotein cholesterol <70 mg\/dL and C-reactive protein <2 mg\/L: an analysis of the PROVE-IT TIMI-22 trial","volume":"45","author":"Ridker","year":"2005","journal-title":"J Intern Med."},{"key":"10.4158\/CS-2020-0490_bb0160","first-page":"247","article-title":"Apo B versus cholesterol in estimating cardiovascular risk and in guiding therapy: report of the thirty-person\/ten-country panel","volume":"259","author":"Barter","year":"2006","journal-title":"Arch Intern Med."},{"key":"10.4158\/CS-2020-0490_bb0165","first-page":"743","article-title":"Gemfibrozil in the treatment of dyslipidemia: an 18-year mortality follow-up of the Helsinki Heart Study","volume":"166","author":"Tenkanen","year":"2006","journal-title":"Atherosclerosis."},{"key":"10.4158\/CS-2020-0490_bb0170","first-page":"135","article-title":"Effects of EPA on coronary artery disease in hypercholesterolemic patients with multiple risk factors: sub-analysis of primary prevention cases from the Japan EPA Lipid Intervention Study (JELIS)","volume":"200","author":"Saito","year":"2008","journal-title":"N Engl J Med."},{"key":"10.4158\/CS-2020-0490_bb0175","first-page":"11","article-title":"Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia","volume":"380","author":"Bhatt","year":"2019","journal-title":"Lancet."},{"key":"10.4158\/CS-2020-0490_bb0180","first-page":"1849","article-title":"Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial","volume":"366","author":"Keech","year":"2005","journal-title":"Cardiovasc Diabetol."},{"key":"10.4158\/CS-2020-0490_bb0185","first-page":"11","article-title":"Bezafibrate for the treatment of dyslipidemia in patients with coronary artery disease: 20-year mortality follow-up of the BIP randomized control trial","volume":"15","author":"Arbel","year":"2016","journal-title":"Circulation."},{"key":"10.4158\/CS-2020-0490_bb0190","first-page":"21","article-title":"Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease","volume":"102","year":"2000","journal-title":"N Engl J Med."},{"key":"10.4158\/CS-2020-0490_bb0195","first-page":"410","article-title":"Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group","volume":"341","author":"Rubins","year":"1999","journal-title":"JAMA."},{"key":"10.4158\/CS-2020-0490_bb0200","first-page":"1585","article-title":"Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial","volume":"285","author":"Robins","year":"2001","journal-title":"N Engl J Med."},{"key":"10.4158\/CS-2020-0490_bb0205","first-page":"e34","article-title":"Primary prevention of cardiovascular disease with a Mediterranean diet supplemented with extra-virgin olive oil or nuts","volume":"378","author":"Estruch","year":"2018","journal-title":"Nutrients."},{"key":"10.4158\/CS-2020-0490_bb0210","first-page":"338","article-title":"DASH dietary pattern and cardiometabolic outcomes: an umbrella review of systematic reviews and meta-analyses","volume":"11","author":"Chiavaroli","year":"2019","journal-title":"Am J Clin Nutr."},{"key":"10.4158\/CS-2020-0490_bb0215","first-page":"93","article-title":"Fruit and vegetable intake and risk of cardiovascular disease in US adults: the first National Health and Nutrition Examination Survey Epidemiologic Follow-up Study","volume":"76","author":"Bazzano","year":"2002","journal-title":"J Fam Pract."},{"key":"10.4158\/CS-2020-0490_bb0220","first-page":"356b","article-title":"A way to reverse CAD?","volume":"63","author":"Esselstyn","year":"2014","journal-title":"JAMA."},{"key":"10.4158\/CS-2020-0490_bb0225","first-page":"2001","article-title":"Intensive lifestyle changes for reversal of coronary heart disease","volume":"280","author":"Ornish","year":"1998","journal-title":"Am J Clin Nutr."},{"key":"10.4158\/CS-2020-0490_bb0230","first-page":"597","article-title":"Risk of hospitalization or death from ischemic heart disease among British vegetarians and nonvegetarians: results from the EPIC-Oxford cohort study","volume":"97","author":"Crowe","year":"2013","journal-title":"J Geriatr Cardiol."},{"key":"10.4158\/CS-2020-0490_bb0235","first-page":"321","article-title":"A plant-based diet and stroke","volume":"14","author":"Campbell","year":"2017","journal-title":"Annu Rev Nutr."},{"key":"10.4158\/CS-2020-0490_bb0240","first-page":"157","article-title":"Trimethylamine N-oxide, the microbiome, and heart and kidney disease","volume":"37","author":"Zeisel","year":"2017","journal-title":"Physical Activity Guidelines for Americans."},{"key":"10.4158\/CS-2020-0490_bb0245","series-title":"Int J Obes Relat Metab Disord.","year":"2018"},{"key":"10.4158\/CS-2020-0490_bb0250","first-page":"893","article-title":"Prescribing exercise in multiple short bouts versus one continuous bout: effects on adherence, cardiorespiratory fitness, and weight loss in over-weight women","volume":"19","author":"Jakicic","year":"1995","journal-title":"Diabetes Care."},{"key":"10.4158\/CS-2020-0490_bb0255","first-page":"2205","article-title":"The effect of resistance training on functional capacity and quality of life in individuals with high and low numbers of metabolic risk factors","volume":"30","author":"Levinger","year":"2007","journal-title":"Prev Med."},{"key":"10.4158\/CS-2020-0490_bb0260","first-page":"9","article-title":"Impact of progressive resistance training on lipids and lipoproteins in adults: a meta-analysis of randomized controlled trials","volume":"48","author":"Kelley","year":"2009","journal-title":"Can J Diabetes."},{"key":"10.4158\/CS-2020-0490_bb0265","first-page":"103","article-title":"Inadequate sleep as a contributor to obesity and type 2 diabetes","volume":"37","author":"McNeil","year":"2013","journal-title":"Eur Heart J."},{"key":"10.4158\/CS-2020-0490_bb0270","first-page":"1484","article-title":"Sleep duration predicts cardiovascular outcomes: a systematic review and meta-analysis of prospective studies","volume":"32","author":"Cappuccio","year":"2011","journal-title":"Am J Epidemiol."},{"key":"10.4158\/CS-2020-0490_bb0275","first-page":"947","article-title":"Association between reduced sleep and weight gain in women","volume":"164","author":"Patel","year":"2006","journal-title":"Sleep."},{"key":"10.4158\/CS-2020-0490_bb0280","first-page":"1009","article-title":"Association of usual sleep duration with hypertension: the Sleep Heart Health Study","volume":"29","author":"Gottlieb","year":"2006","journal-title":"Obesity."},{"key":"10.4158\/CS-2020-0490_bb0285","first-page":"253","article-title":"Short sleep duration is associated with reduced leptin levels and increased adiposity: Results from the Quebec family study","volume":"15","author":"Chaput","year":"2007","journal-title":"Arch Intern Med."},{"key":"10.4158\/CS-2020-0490_bb0290","first-page":"205","article-title":"A prospective study of sleep duration and coronary heart disease in women","volume":"163","author":"Ayas","year":"2003","journal-title":"Dialogues Clin Neurosci."},{"key":"10.4158\/CS-2020-0490_bb0295","first-page":"31","article-title":"The intriguing relationship between coronary heart disease and mental disorders","volume":"20","author":"De Hert","year":"2018","journal-title":"Curr Cardiol Rep."},{"key":"10.4158\/CS-2020-0490_bb0300","first-page":"106","article-title":"The Protective Role of Positive Well-being in cardiovascular disease: review of current evidence, mechanisms, and clinical implications","volume":"18","author":"Sin","year":"2016","journal-title":"Prev Med."},{"key":"10.4158\/CS-2020-0490_bb0305","first-page":"613","article-title":"A meta-analysis of alcohol consumption and the risk of 15 diseases","volume":"38","author":"Corrao","year":"2004","journal-title":"Circulation."},{"key":"10.4158\/CS-2020-0490_bb0310","first-page":"1951","article-title":"Cardiovascular and overall mortality risk in relation to alcohol consumption in patients with cardiovascular disease","volume":"121","author":"Costanzo","year":"2010","journal-title":"Int J Mol Sci."},{"key":"10.4158\/CS-2020-0490_bb0315","series-title":"Is drinking alcohol part of a healthy lifestyle?","year":"2019"},{"key":"10.4158\/CS-2020-0490_bb0320","first-page":"584","article-title":"Acute and chronic effects of cocaine on cardiovascular health","volume":"20","author":"Kim","year":"2019","journal-title":"The Health Consequences of Smoking\u201350 Years of Progress: A Report of the Surgeon General."},{"key":"10.4158\/CS-2020-0490_bb0325","series-title":"The Health Consequences of Smoking\u201350 Years of Progress: A Report of the Surgeon General.","year":"2014"},{"key":"10.4158\/CS-2020-0490_bb0330","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","article-title":"Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials","volume":"376","author":"Baigent","year":"2010","journal-title":"Lancet."},{"key":"10.4158\/CS-2020-0490_bb0335","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.jacc.2014.02.615","article-title":"Very low levels of atherogenic lipoproteins and the risk for cardiovascular events: a meta-analysis of statin trials","volume":"64","author":"Boekholdt","year":"2014","journal-title":"J Am Coll Cardiol."},{"key":"10.4158\/CS-2020-0490_bb0340","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0140-6736(08)60104-X","article-title":"Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis","volume":"371","author":"Kearney","year":"2008","journal-title":"Lancet."},{"key":"10.4158\/CS-2020-0490_bb0345","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1001\/jama.292.11.1307","article-title":"Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial","volume":"292","author":"de Lemos","year":"2004","journal-title":"JAMA."},{"key":"10.4158\/CS-2020-0490_bb0350","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s10557-005-5686-z","article-title":"Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients\u2013the PRIMO study","volume":"19","author":"Bruckert","year":"2005","journal-title":"Cardiovasc Drugs Ther."},{"key":"10.4158\/CS-2020-0490_bb0355","doi-asserted-by":"crossref","first-page":"1962","DOI":"10.1016\/S0140-6736(17)32290-0","article-title":"Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial","volume":"390","author":"Giugliano","year":"2017","journal-title":"Lancet."},{"key":"10.4158\/CS-2020-0490_bb0360","series-title":"Nexletol (bempedoic acid) prescribing information","year":"2020"},{"key":"10.4158\/CS-2020-0490_bb0365","series-title":"Welchol (colesevelam hydrochloride) prescribing information","year":"2019"},{"key":"10.4158\/CS-2020-0490_bb0370","series-title":"Praluent (alirocumab) prescribing information","year":"2020"},{"key":"10.4158\/CS-2020-0490_bb0375","series-title":"Repatha (evolocumab) prescribing information","year":"2019"},{"key":"10.4158\/CS-2020-0490_bb0380","series-title":"Zetia (ezetimibe) prescribing information","year":"2013"},{"key":"10.4158\/CS-2020-0490_bb0385","series-title":"Crestor (rosuvastatin) prescribing information","year":"2018"},{"key":"10.4158\/CS-2020-0490_bb0390","series-title":"Lipitor (atorvastatin) prescribing information","year":"2019"},{"key":"10.4158\/CS-2020-0490_bb0395","series-title":"Zocor (simvastatin) prescribing information","year":"2019"},{"key":"10.4158\/CS-2020-0490_bb0400","series-title":"Livalo (pitavastatin) prescribing information","year":"2019"},{"key":"10.4158\/CS-2020-0490_bb0405","series-title":"Lescol\/Lescol XL (fluvastatin\/fluvastatin extended release) prescribing information","year":"2017"},{"key":"10.4158\/CS-2020-0490_bb0410","series-title":"Pravachol (pravastatin) prescribing information","year":"2016"},{"key":"10.4158\/CS-2020-0490_bb0415","series-title":"Mevacor (lovastatin) prescribing information","year":"2012"},{"key":"10.4158\/CS-2020-0490_bb0420","first-page":"S35","article-title":"Diagnosis, prevention, and management of statin adverse effects and intolerance: Canadian Consensus Working Group update (2016)","volume":"32","author":"Mancini","year":"2016","journal-title":"Can J Cardiol."},{"key":"10.4158\/CS-2020-0490_bb0425","doi-asserted-by":"crossref","first-page":"e38","DOI":"10.1161\/ATV.0000000000000073","article-title":"Statin safety and associated adverse events: a scientific statement from the American Heart Association","volume":"39","author":"Newman","year":"2019","journal-title":"Arterioscler Thromb Vasc Biol."},{"key":"10.4158\/CS-2020-0490_bb0430","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1093\/eurheartj\/ehv043","article-title":"Statin-associated muscle symptoms: impact on statin therapy\u2013European Atherosclerosis Society Consensus Panel statement on assessment, aetiology and management","volume":"36","author":"Stroes","year":"2015","journal-title":"Eur Heart J."},{"key":"10.4158\/CS-2020-0490_bb0435","doi-asserted-by":"crossref","first-page":"e","DOI":"10.1161\/JAHA.118.009835","article-title":"Effects of coenzyme Q10 on statin-induced myopathy: an updated meta-analysis of randomized controlled trials","volume":"7","author":"Qu","year":"2018","journal-title":"J Am Heart Assoc."},{"key":"10.4158\/CS-2020-0490_bb0440","doi-asserted-by":"crossref","first-page":"2526","DOI":"10.1093\/eurheartj\/ehy182","article-title":"Adverse effects of statin therapy: perception vs. the evidence\u2013focus on glucose homeostasis, cognitive, renal and hepatic function, haemorrhagic stroke and cataract","volume":"39","author":"Mach","year":"2018","journal-title":"Eur Heart J."},{"key":"10.4158\/CS-2020-0490_bb0445","doi-asserted-by":"crossref","first-page":"107","DOI":"10.4158\/CS-2019-0472","article-title":"Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Comprehensive Type 2 Diabetes Management Algorithm\u20132020 Executive Summary","volume":"26","author":"Garber","year":"2020","journal-title":"Endocr Pract."},{"key":"10.4158\/CS-2020-0490_bb0450","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4158\/EP15672.GLSUPPL","article-title":"American Association of Clinical Endocrinologists and American College of Endocrinology: clinical practice guidelines for developing a diabetes mellitus comprehensive care plan\u20132015","volume":"21","author":"Handelsman","year":"2015","journal-title":"Endocr Pract."},{"key":"10.4158\/CS-2020-0490_bb0455","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1001\/jama.285.19.2486","article-title":"Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)","volume":"285","year":"2001","journal-title":"JAMA."},{"key":"10.4158\/CS-2020-0490_bb0460","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/S0140-6736(14)61177-6","article-title":"Triglycerides and cardiovascular disease","volume":"384","author":"Nordestgaard","year":"2014","journal-title":"Lancet."},{"key":"10.4158\/CS-2020-0490_bb0465","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1001\/jama.2018.20045","article-title":"Association of triglyceride-lowering LPL variants and LDL-C-lowering LDLR variants with risk of coronary heart disease","volume":"321","author":"Ference","year":"2019","journal-title":"JAMA."},{"key":"10.4158\/CS-2020-0490_bb0470","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1056\/NEJMoa1001282","article-title":"Effects of combination lipid therapy in type 2 diabetes mellitus","volume":"362","author":"Ginsberg","year":"2010","journal-title":"N Engl J Med."},{"key":"10.4158\/CS-2020-0490_bb0475","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/S0140-6736(05)67667-2","article-title":"Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial","volume":"366","year":"2005","journal-title":"Lancet."},{"key":"10.4158\/CS-2020-0490_bb0480","series-title":"Vascepa (icosapent ethyl) prescribing information","year":"2019"},{"key":"10.4158\/CS-2020-0490_bb0485","doi-asserted-by":"crossref","first-page":"e0205006","DOI":"10.1371\/journal.pone.0205006","article-title":"Effect of fenofibrate in 1113 patients at low-density lipoprotein cholesterol goal but high triglyceride levels: Real-world results and factors associated with triglyceride reduction","volume":"13","author":"Woo","year":"2018","journal-title":"PLoS One."},{"key":"10.4158\/CS-2020-0490_bb0490","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S0378-5122(01)00302-4","article-title":"Effects of a lipid lowering fibrate and hormone replacement therapy on serum lipids and lipoproteins in overweight postmenopausal women with elevated triglycerides","volume":"42","author":"Nerbrand","year":"2002","journal-title":"Maturitas."},{"key":"10.4158\/CS-2020-0490_bb0495","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1093\/eurheartj\/ehr112","article-title":"Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management","volume":"32","author":"Chapman","year":"2011","journal-title":"Eur Heart J."},{"key":"10.4158\/CS-2020-0490_bb0500","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1016\/j.clinthera.2007.07.018","article-title":"Efficacy and tolerability of adding prescription omega-3 fatty acids 4 g\/d to simvastatin 40 mg\/d in hypertriglyceridemic patients: an 8-week, randomized, double-blind, placebo-controlled study","volume":"29","author":"Davidson","year":"2007","journal-title":"Clin Ther."},{"key":"10.4158\/CS-2020-0490_bb0505","series-title":"Lovaza (omega-3-acid ethyl esters) prescribing information","year":"2019"},{"key":"10.4158\/CS-2020-0490_bb0510","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1111\/j.1365-2125.2012.04374.x","article-title":"Omega-3 polyunsaturated fatty acids and inflammatory processes: nutrition or pharmacology?","volume":"75","author":"Calder","year":"2013","journal-title":"Br J Clin Pharmacol."},{"key":"10.4158\/CS-2020-0490_bb0515","doi-asserted-by":"crossref","first-page":"2586","DOI":"10.1194\/jlr.R040592","article-title":"Niacin, an old drug with a new twist","volume":"54","author":"Song","year":"2013","journal-title":"J Lipid Res."},{"key":"10.4158\/CS-2020-0490_bb0520","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1016\/j.jacl.2017.08.005","article-title":"Niacin and heart disease prevention: Engraving its tombstone is a mistake","volume":"11","author":"Superko","year":"2017","journal-title":"J Clin Lipidol."},{"key":"10.4158\/CS-2020-0490_bb0525","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1016\/j.jacl.2018.03.086","article-title":"Clinical features and outcomes of severe, very severe, and extreme hypertriglyceridemia in a regional health service","volume":"12","author":"Zafrir","year":"2018","journal-title":"J Clin Lipidol."},{"key":"10.4158\/CS-2020-0490_bb0530","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.amjmed.2013.09.018","article-title":"Determining triglyceride reductions needed for clinical impact in severe hypertriglyceridemia","volume":"127","author":"Christian","year":"2014","journal-title":"Am J Med."},{"key":"10.4158\/CS-2020-0490_bb0535","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/S0002-9149(03)00530-7","article-title":"Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR Trial)","volume":"92","author":"Jones","year":"2003","journal-title":"Am J Cardiol."},{"key":"10.4158\/CS-2020-0490_bb0540","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/S0002-9149(97)00965-X","article-title":"Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES Study)","volume":"81","author":"Jones","year":"1998","journal-title":"Am J Cardiol."},{"key":"10.4158\/CS-2020-0490_bb0545","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.2337\/diacare.24.8.1335","article-title":"The effect of aggressive versus standard lipid lowering by atorvastatin on diabetic dyslipidemia: the DALI study: a double-blind, randomized, placebo-controlled trial in patients with type 2 diabetes and diabetic dyslipidemia","volume":"24","year":"2001","journal-title":"Diabetes Care."},{"key":"10.4158\/CS-2020-0490_bb0550","doi-asserted-by":"crossref","first-page":"2791","DOI":"10.1016\/j.jacc.2019.02.032","article-title":"Effects of icosapent ethyl on total ischemic events: From REDUCE-IT","volume":"73","author":"Bhatt","year":"2019","journal-title":"J Am Coll Cardiol."},{"key":"10.4158\/CS-2020-0490_bb0555","series-title":"EPA levels and cardiovascular outcomes in the reduction of cardiovascular events with icosapent ethyl\u2013intervention trial (REDUCE-IT)","author":"Bhatt","year":"2020"},{"key":"10.4158\/CS-2020-0490_bb0560","doi-asserted-by":"crossref","first-page":"1645S","DOI":"10.1093\/ajcn\/65.5.1645S","article-title":"n-3 fatty acids and serum lipoproteins: human studies","volume":"65","author":"Harris","year":"1997","journal-title":"Am J Clin Nutr."},{"key":"10.4158\/CS-2020-0490_bb0565","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/S0021-9150(98)00301-3","article-title":"Correlation of serum triglyceride and its reduction by omega-3 fatty acids with lipid transfer activity and the neutral lipid compositions of high-density and low-density lipoproteins","volume":"143","author":"Pownall","year":"1999","journal-title":"Atherosclerosis."},{"key":"10.4158\/CS-2020-0490_bb0570","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1097\/MOL.0000000000000665","article-title":"Are dietary fish oil supplements appropriate for dyslipidemia management? A review of the evidence","volume":"31","author":"Sherratt","year":"2020","journal-title":"Curr Opin Lipidol."},{"key":"10.4158\/CS-2020-0490_bb0575","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1001\/jama.2009.1063","article-title":"Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality","volume":"302","author":"Erqou","year":"2009","journal-title":"JAMA."},{"key":"10.4158\/CS-2020-0490_bb0580","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/j.jacc.2014.03.061","article-title":"Discrimination and net reclassification of cardiovascular risk with lipoprotein(a): prospective 15-year outcomes in the Bruneck Study","volume":"64","author":"Willeit","year":"2014","journal-title":"J Am Coll Cardiol."},{"key":"10.4158\/CS-2020-0490_bb0585","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1097\/MED.0000000000000237","article-title":"Lipoprotein(a): novel target and emergence of novel therapies to lower cardiovascular disease risk","volume":"23","author":"Tsimikas","year":"2016","journal-title":"Curr Opin Endocrinol Diabetes Obes."},{"key":"10.4158\/CS-2020-0490_bb0590","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1016\/S0140-6736(18)31652-0","article-title":"Baseline and on-statin treatment lipoprotein(a) levels for prediction of cardiovascular events: individual patient-data meta-analysis of statin outcome trials","volume":"392","author":"Willeit","year":"2018","journal-title":"Lancet."},{"key":"10.4158\/CS-2020-0490_bb0595","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1161\/CIRCULATIONAHA.118.037184","article-title":"Lipoprotein(a), PCSK9 Inhibition, and Cardiovascular Risk","volume":"139","author":"O\u2019Donoghue","year":"2019","journal-title":"Circulation."},{"key":"10.4158\/CS-2020-0490_bb0600","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.jstrokecerebrovasdis.2007.05.003","article-title":"Effect of aspirin on lipoprotein(a) in patients with ischemic stroke","volume":"16","author":"Ranga","year":"2007","journal-title":"J Stroke Cerebrovasc Dis."},{"key":"10.4158\/CS-2020-0490_bb0605","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.jacc.2008.04.009","article-title":"Lipoprotein(a), hormone replacement therapy, and risk of future cardiovascular events","volume":"52","author":"Suk Danik","year":"2008","journal-title":"J Am Coll Cardiol."},{"key":"10.4158\/CS-2020-0490_bb0610","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1016\/j.metabol.2016.08.007","article-title":"Effect of extended-release niacin on plasma lipoprotein(a) levels: A systematic review and meta-analysis of randomized placebo-controlled trials","volume":"65","author":"Sahebkar","year":"2016","journal-title":"Metabolism."},{"key":"10.4158\/CS-2020-0490_bb0615","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.atherosclerosissup.2017.05.004","article-title":"Specific Lp(a) apheresis: A tool to prove lipoprotein(a) atherogenicity","volume":"30","author":"Pokrovsky","year":"2017","journal-title":"Atheroscler Suppl."},{"key":"10.4158\/CS-2020-0490_bb0620","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","article-title":"Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials","volume":"376","author":"Baigent","year":"2010","journal-title":"Lancet."},{"key":"10.4158\/CS-2020-0490_bb0625","doi-asserted-by":"crossref","first-page":"2556","DOI":"10.1001\/jama.2011.860","article-title":"Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis","volume":"305","author":"Preiss","year":"2011","journal-title":"JAMA."},{"key":"10.4158\/CS-2020-0490_bb0630","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1007\/s00125-015-3528-5","article-title":"Increased risk of diabetes with statin treatment is associated with impaired insulin sensitivity and insulin secretion: a 6 year follow-up study of the METSIM cohort","volume":"58","author":"Cederberg","year":"2015","journal-title":"Diabetologia."},{"key":"10.4158\/CS-2020-0490_bb0635","series-title":"FDA drug safety communication: important safety label changes to cholesterol-lowering statin drugs","year":"2012"},{"key":"10.4158\/CS-2020-0490_bb0640","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s11894-017-0584-7","article-title":"Use of statins in patients with chronic liver disease and cirrhosis: current views and prospects","volume":"19","author":"Vargas","year":"2017","journal-title":"Curr Gastroenterol Rep."},{"key":"10.4158\/CS-2020-0490_bb0645","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.atherosclerosis.2018.06.002","article-title":"Efficacy and safety of bempedoic acid added to ezetimibe in statin-intolerant patients with hypercholesterolemia: A randomized, placebo-controlled study","volume":"277","author":"Ballantyne","year":"2018","journal-title":"Atherosclerosis."},{"key":"10.4158\/CS-2020-0490_bb0650","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1056\/NEJMoa1803917","article-title":"Safety and efficacy of bempedoic acid to reduce ldl cholesterol","volume":"380","author":"Ray","year":"2019","journal-title":"N Engl J Med."},{"key":"10.4158\/CS-2020-0490_bb0655","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1001\/jama.2019.16585","article-title":"Effect of bempedoic acid vs placebo added to maximally tolerated statins on low-density lipoprotein cholesterol in patients at high risk for cardiovascular disease: The CLEAR Wisdom randomized clinical trial","volume":"322","author":"Goldberg","year":"2019","journal-title":"JAMA."},{"key":"10.4158\/CS-2020-0490_bb0660","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/MOL.0000000000000565","article-title":"Bempedoic acid: effects on lipoprotein metabolism and atherosclerosis","volume":"30","author":"Burke","year":"2019","journal-title":"Curr Opin Lipidol."},{"key":"10.4158\/CS-2020-0490_bb0665","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1177\/2047487319864671","article-title":"Bempedoic acid plus ezetimibe fixed-dose combination in patients with hypercholesterolemia and high CVD risk treated with maximally tolerated statin therapy","volume":"27","author":"Ballantyne","year":"2020","journal-title":"Eur J Prev Cardiol."},{"key":"10.4158\/CS-2020-0490_bb0670","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1007\/s00125-010-1951-1","article-title":"Effects of fenofibrate on renal function in patients with type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study","volume":"54","author":"Davis","year":"2011","journal-title":"Diabetologia."},{"key":"10.4158\/CS-2020-0490_bb0675","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1056\/NEJMoa1107579","article-title":"Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy","volume":"365","author":"Boden","year":"2011","journal-title":"N Engl J Med."},{"key":"10.4158\/CS-2020-0490_bb0680","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1056\/NEJMoa1300955","article-title":"Effects of extended-release niacin with laropiprant in high-risk patients","volume":"371","author":"Landray","year":"2014","journal-title":"N Engl J Med."},{"key":"10.4158\/CS-2020-0490_bb0685","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.atherosclerosissup.2015.02.008","article-title":"Lowering of lipoprotein(a) level under niacin treatment is dependent on apolipoprotein(a) phenotype","volume":"18","author":"Artemeva","year":"2015","journal-title":"Atheroscler Suppl."},{"key":"10.4158\/CS-2020-0490_bb0690","series-title":"Juxtapid (lomitapide) prescribing information","year":"2017"}],"container-title":["Endocrine Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X20482047?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X20482047?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T22:09:59Z","timestamp":1761516599000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1530891X20482047"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10]]},"references-count":135,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["S1530891X20482047"],"URL":"https:\/\/doi.org\/10.4158\/cs-2020-0490","relation":{},"ISSN":["1530-891X"],"issn-type":[{"value":"1530-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2020,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Management of Dyslipidemia and Prevention of Cardiovascular Disease Algorithm \u2013 2020 Executive Summary","name":"articletitle","label":"Article Title"},{"value":"Endocrine Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.4158\/CS-2020-0490","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}